Clinical applications of angiogenic growth factors and their inhibitors.
Promoting the formation of new collateral vessels in ischemic tissues using angiogenic growth factors (therapeutic angiogenesis) is a an exciting frontier of cardiovascular medicine. Conversely, inhibition of the action of key regulators of angiogenesis, such as VEGF, constitutes a promising approach for the treatment of solid tumors and intraocular neovascular syndromes. These concepts are being tested now in clinical trials.
Ferrara
N
N
Department of Molecular Oncology Genentech DNA Way South San Francisco, California 94080, USA. nf@gene.com
Alitalo
K
K
D000818:Animals; D003327:Coronary Disease / Q000188:drug therapy; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000627:therapeutic use*; D006131:Growth Inhibitors / Q000627:therapeutic use*; D006801:Humans; D007511:Ischemia / Q000188:drug therapy; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000627:therapeutic use*; D051379:Mice; D018345:Mice, Knockout; D009374:Neoplasms, Experimental / Q000098:blood supply / Q000188:drug therapy; D009389:Neovascularization, Pathologic / Q000188:drug therapy / Q000517:prevention & control; D018919:Neovascularization, Physiologic / Q000187:drug effects*; D011994:Recombinant Proteins / Q000627:therapeutic use; D012169:Retinal Vein / Q000187:drug effects; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D006131:Growth Inhibitors; D008222:Lymphokines; D011994:Recombinant Proteins; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors